Screener / SEC EDGAR /CIK 0001082554 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

UNITED THERAPEUTICS Corp UTHR

Compare with peers Embed
Planned sales, announced before they happen

1 trading plan running, 92 Form 144 notices for $1.5B

10-Q, 10-K and Form 144

What UTHR's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Dec 24, 2024 to Dec 31, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Christopher Patusky
member of our Board of Directors
Adopted 10b5-1 plan Dec 18, 2025 10-K Feb 25, 2026
What the company wrote
On December 18, 2025, Christopher Patusky, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 4,910 stock options and sell the shares of common stock received, subject to certain conditions.
Dr. Martine Rothblatt
Chairperson and Chief Executive Officer
Adopted 10b5-1 plan Nov 7, 2025 10-K Feb 25, 2026
What the company wrote
On November 7, 2025, Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 1,734,410 stock options and sell the shares of our common stock received, subject to certain conditions. These transactions would commence no earlier than March 2, 2026, and end no later than December 31, 2026, ahead of the anticipated expiration date of these options, which is March 15, 2027. The 1,734,410 stock options covered by this trading plan include options that will be owned by a trust of which Dr. Rothblatt was settlor and in which she has a pecuniary interest.
Judy Olian
member of our Board of Directors
Adopted 10b5-1 plan Nov 4, 2025 10-K Feb 25, 2026
What the company wrote
On November 4, 2025, Judy Olian, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 800 shares of our common stock, subject to certain conditions.
James Edgemond
Chief Financial Officer and Treasurer
Adopted 10b5-1 plan Oct 31, 2025 10-K Feb 25, 2026
What the company wrote
On October 31, 2025, James Edgemond, Chief Financial Officer and Treasurer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 268,750 stock options and sell the shares of common stock received, subject to certain conditions.
Christopher Causey
member of our Board of Directors
Adopted 10b5-1 plan Sep 30, 2025 10-Q Oct 29, 2025
What the company wrote
On September 30, 2025, Christopher Causey, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 4,320 stock options and sell the shares of common stock received, subject to certain conditions.
Jan Malcolm
member of our Board of Directors
Adopted 10b5-1 plan Sep 11, 2025 10-Q Oct 29, 2025
What the company wrote
On September 11, 2025, Jan Malcolm, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 720 shares of our common stock, subject to certain conditions.
Paul Mahon
Section 16 officer
Adopted 10b5-1 plan Aug 11, 2025 10-Q Oct 29, 2025
What the company wrote
On August 11, 2025, Paul Mahon, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 196,940 stock options and sell the shares of common stock received, subject to certain conditions.
James Edgemond
Section 16 officer
Adopted 10b5-1 plan Aug 5, 2025 10-Q Oct 29, 2025
What the company wrote
On August 5, 2025, James Edgemond, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 129,517 stock options and sell the shares of our common stock received, subject to certain conditions.
Christopher Causey
member of our Board of Directors
Adopted 10b5-1 plan Dec 24, 2024 10-K Feb 26, 2025
What the company wrote
On December 24, 2024, Christopher Causey, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 3,000 stock options and sell the shares of common stock received, subject to certain conditions.
Paul Mahon
Section 16 officer
Adopted 10b5-1 plan Dec 24, 2024 10-K Feb 26, 2025
What the company wrote
On December 24, 2024, Paul Mahon, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 220,000 stock options and sell the shares of common stock received, subject to certain conditions.
James Edgemond
Section 16 officer
Adopted 10b5-1 plan Nov 6, 2024 10-K Feb 26, 2025
What the company wrote
On November 6, 2024, James Edgemond, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 111,500 stock options and sell the shares of common stock received, subject to certain conditions.
Christopher Patusky
member of our Board of Directors
Adopted 10b5-1 plan Aug 27, 2024 10-Q Oct 30, 2024
What the company wrote
On August 27, 2024, Christopher Patusky, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 10,000 stock options and sell the shares of common stock received, subject to certain conditions.
Michael Benkowitz
Section 16 officer
Adopted 10b5-1 plan Aug 7, 2024 10-Q Oct 30, 2024
What the company wrote
On August 7, 2024, trusts beneficially owned by Michael Benkowitz, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 201,679 stock options and sell the shares of common stock received, subject to certain conditions.
Raymond Dwek
member of our Board of Directors
Adopted 10b5-1 plan Aug 2, 2024 10-Q Oct 30, 2024
What the company wrote
On August 2, 2024, Raymond Dwek, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 10,000 stock options and sell the shares of common stock received, subject to certain conditions.
Paul Mahon
Section 16 officer
Adopted 10b5-1 plan Jun 20, 2024 10-Q Jul 31, 2024
What the company wrote
On June 20, 2024, Paul Mahon, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 91,250 STAP awards, subject to certain conditions.
James Edgemond
Section 16 officer
Adopted 10b5-1 plan May 17, 2024 10-Q Jul 31, 2024
What the company wrote
On May 17, 2024, James Edgemond, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 100,000 stock options, and to sell up to 80,000 shares of common stock received upon exercise of such stock options, subject to certain conditions.
Raymond Dwek
director
Adopted 10b5-1 plan Nov 27, 2023 10-K Feb 21, 2024
What the company wrote
On November 27, 2023, Raymond Dwek, a director of the company, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 10,000 STAP awards between April 8, 2024 and April 26, 2024, subject to certain conditions. These STAP awards are scheduled to expire on June 26, 2024.
Dr. Martine Rothblatt
Chairperson and Chief Executive Officer
Adopted 10b5-1 plan Aug 4, 2023 10-Q Nov 1, 2023
What the company wrote
On August 4, 2023, Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 723,869 stock options and sell the shares of our common stock issued upon exercise between November 6, 2023 and August 31, 2024, subject to certain conditions. These stock options expire December 31, 2024.
Dr. Martine Rothblatt
Chairperson and Chief Executive Officer
Adopted 10b5-1 plan – 10-Q Jul 30, 2025
What the company wrote
On May 2, 2025, Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 294,000 stock options and sell the shares of our common stock received, subject to certain conditions. These stock options expire in March 2026.
Michael Benkowitz
Section 16 officer
Adopted 10b5-1 plan – 10-Q Jul 30, 2025
What the company wrote
On June 3, 2025, trusts beneficially owned by Michael Benkowitz, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 576,940 stock options and sell the shares of common stock received, subject to certain conditions. These stock options expire in March 2027.
Show the other 12 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 3, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 9, 2026 CHRISTOPHER PATUSKY
Director
1,210 $702K
Nov 5, 2026 PAUL MAHON
Officer
8,300 $5.0M
Nov 2, 2026 MARTINE ROTHBLATT
Director, Officer
119,410 $71.5M
Oct 15, 2026 PAUL MAHON
Officer
8,300 $4.5M
Oct 1, 2026 MARTINE ROTHBLATT
Director, Officer
209,000 $113.3M
Oct 1, 2026 PAUL MAHON
Officer
8,300 $4.7M
Sep 17, 2026 PAUL MAHON
Officer
8,300 $4.1M
Sep 14, 2026 NILDA MESA
Director
228 $115K
Sep 3, 2026 PAUL MAHON
Officer
8,300 $4.0M
Sep 1, 2026 MARTINE ROTHBLATT
Officer
199,500 $101.8M
Aug 20, 2026 PAUL MAHON
Officer
8,300 $4.3M
Aug 6, 2026 PAUL MAHON
Officer
8,300 $4.3M
Aug 3, 2026 MARTINE ROTHBLATT
Director, Officer
199,500 $103.3M
Jul 16, 2026 PAUL A. MAHON
Officer
8,300 $4.4M
Jul 10, 2026 JAN MALCOLM
Director
325 $179K
Jul 2, 2026 PAUL MAHON
Officer
8,300 $4.6M
Jul 1, 2026 MARTINE ROTHBLATT
Director, Officer
209,000 $113.2M
Jun 18, 2026 PAUL MAHON
Officer
8,300 $4.5M
Jun 4, 2026 PAUL MAHON
Officer
8,300 $4.5M
Jun 1, 2026 MARTINE ROTHBLATT
Director, Officer
199,500 $111.1M
May 21, 2026 PAUL MAHON
Officer
8,300 $4.7M
May 12, 2026 NILDA MESA
Director
258 $150K
May 7, 2026 PAUL MAHON
Officer
8,300 $4.9M
May 4, 2026 JAMES C EDGEMOND
Officer
148,750 $84.8M
May 1, 2026 MARTINE ROTHBLATT
Officer
190,000 $108.6M
Apr 24, 2026 CHRISTOPHER PATUSKY
Director
2,910 $1.7M
Apr 17, 2026 CHRISTOPHER PATUSKY
Director
1,000 $579K
Apr 16, 2026 PAUL MAHON
Officer
8,300 $4.8M
Apr 2, 2026 PAUL MAHON
Officer
8,300 $4.7M
Apr 1, 2026 MARTINE ROTHBLATT
Director, Officer
199,500 $118.3M
Mar 30, 2026 CHRISTOPHER CAUSEY
Director
1,300 $786K
Mar 26, 2026 TOMMY THOMPSON
Director
2,000 $1.1M
Mar 23, 2026 JAMES C EDGEMOND
Officer
120,000 $62.9M
Mar 23, 2026 JUDY OLIAN
Director
200 $106K
Mar 19, 2026 PAUL MAHON
Officer
8,300 $4.4M
Mar 17, 2026 JAN MALCOLM
Director
45 $24K
Mar 16, 2026 JUDY OLIAN
Director
200 $107K
Mar 9, 2026 JUDY OLIAN
Director
200 $102K
Mar 5, 2026 PAUL MAHON
Officer
8,300 $4.0M
Mar 4, 2026 CHRISTOPHER CAUSEY
Director
20 $10K
Mar 4, 2026 TOMMY THOMPSON
Director
2,000 $979K
Mar 4, 2026 RAYMOND KURZWEIL
Director
4,910 $2.4M
Mar 3, 2026 JAN MALCOLM
Director
50 $25K
Mar 2, 2026 MARTINE ROTHBLATT
Director, Officer
209,000 $105.3M
Mar 2, 2026 JUDY OLIAN
Director
200 $102K
Feb 25, 2026 CHRISTOPHER CAUSEY
Director
1,000 $520K
Feb 19, 2026 PAUL MAHON
Officer
8,300 $4.0M
Feb 17, 2026 JAN MALCOLM
Director
50 $24K
Feb 5, 2026 PAUL MAHON
Officer
8,300 $4.0M
Feb 3, 2026 JAN MALCOLM
Director
50 $24K
Feb 2, 2026 Michael Benkowitz
Officer
90,000 $42.3M
Jan 20, 2026 JAN MALCOLM
Director
50 $23K
Jan 15, 2026 PAUL MAHON
Officer
8,300 $3.9M
Jan 6, 2026 CHRISTOPHER CAUSEY
Director
1,000 $510K
Jan 6, 2026 JAN MALCOLM
Director
50 $25K
Jan 5, 2026 Michael Benkowitz
Officer
90,000 $44.7M
Jan 2, 2026 CHRISTOPHER CAUSEY
Director
1,000 $500K
Jan 2, 2026 PAUL MAHON
Officer
8,300 $4.0M
Dec 29, 2025 PAUL MAHON
Officer
11,000 $5.6M
Dec 22, 2025 LOUIS WADE SULLIVAN REVOCABLE TRUST
Affiliate
5,950 $3.0M
Dec 19, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
2,000 $1.0M
Dec 18, 2025 TOMMY THOMPSON
Director
910 $456K
Dec 18, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $2.0M
Dec 17, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $2.0M
Dec 16, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $2.0M
Dec 15, 2025 CHRISTOPHER PATUSKY
Director
1,000 $496K
Dec 15, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $2.0M
Dec 12, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $2.0M
Dec 11, 2025 PAUL MAHON
Officer
11,000 $5.3M
Dec 11, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 10, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 9, 2025 NILDA MESA
Director
187 $90K
Dec 9, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 8, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 5, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 4, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 3, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 2, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Dec 1, 2025 JAMES EDGEMOND
Officer
105,000 $51.0M
Dec 1, 2025 Michael Benkowitz
Officer
112,500 $54.7M
Dec 1, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 28, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $2.0M
Nov 26, 2025 PAUL MAHON
Officer
11,000 $5.3M
Nov 26, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 25, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 24, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 21, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 20, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 19, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 18, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 17, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Nov 14, 2025 ROTHBLATT MARTINE A
FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
4,000 $1.9M
Show the other 84 notices

From the Form 144 XML filed with the SEC, since Nov 14, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UTHR/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.